Timberlyne Therapeutics Funding: $180M Raised, Series A
Timberlyne Therapeutics is a Biotech company based in San Diego, California. It has raised $180M in total funding. Latest round: Series A.
Timberlyne Therapeutics funding overview
Timberlyne Therapeutics is a Biotech company based in San Diego, California. Timberlyne Therapeutics has raised $180M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in January 2025. The round record for Timberlyne Therapeutics runs through 2025; nothing later has been disclosed. Investors on record include Abingworth, Bain Capital Life Sciences, Venrock Healthcare Capital Partners, Boyu Capital, Lilly Asia Ventures, Braidwell LP and 1 others. 7 distinct backers are named across the disclosed rounds.
Timberlyne Therapeutics at a glance
Total raised
$180M
Latest round
Series A
Latest round date
January 2025
Industry
Biotech
Headquarters
San Diego, California
Notable investors
Abingworth, Bain Capital Life Sciences, Venrock Healthcare Capital Partners, Boyu Capital, Lilly Asia Ventures, Braidwell LP, 3H Health Investment
Frequently asked about Timberlyne Therapeutics funding
How much has Timberlyne Therapeutics raised?
Timberlyne Therapeutics has raised $180M in total disclosed funding across the rounds on record.
Who has invested in Timberlyne Therapeutics?
Abingworth, Bain Capital Life Sciences, Venrock Healthcare Capital Partners, Boyu Capital, Lilly Asia Ventures, Braidwell LP are named among the investors backing Timberlyne Therapeutics.
What was the latest Timberlyne Therapeutics funding round?
The most recent disclosed round is a Series A, announced in January 2025.
Where is Timberlyne Therapeutics based?
Timberlyne Therapeutics is based in San Diego, California.
What sector does Timberlyne Therapeutics operate in?
Timberlyne Therapeutics is tracked under Biotech from San Diego, California, with $180M in disclosed funding.
When did Timberlyne Therapeutics last raise?
The last disclosed Timberlyne Therapeutics round closed in January 2025 at Series A.
Timberlyne Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in San Diego below to benchmark round size and investor mix.
